In 2017, the US Food and Drug Administration approved the drugs tisagenlecleucel (Kymriah; Novartis) and axicabtagene ciloleucel (Yescarta; Kite Pharma) as the first chimeric antigen receptor T-cell (CAR-T) immunotherapies. Treatment with tisagenlecleucel has been priced at $475 000 and axicabtagene ciloleucel at $373 000; however, these prices are for the drug products alone and do not account for the costs associated with leukapheresis, lymphodepletion therapy, and the adverse effects of CAR-T immunotherapy. These costs are not negligible as 43 patients (44%) who received tisagenlecleucel in clinical trials required stays in the intensive care unit for cytokine release syndrome (CRS).1 In this study, we estimated the total costs of CAR-T immunotherapy, including nondrug costs, using publicly available data.
Hernandez I, Prasad V, Gellad WF. Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy. JAMA Oncol. 2018;4(7):994–996. doi:10.1001/jamaoncol.2018.0977
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: